Federal contract award
75A50119C00016
DEMONSTRATE LARGE ANIMAL EFFICACY, DEFINE PROTOCOLS FOR THE PIVOTAL ANIMAL TRIAL, AND BETTER UNDERSTAND THE PHARMACODYNAMICS OF TP508. TO ACHIEVE THIS OBJECTIVE, WE WILL CONDUCT NON-CLINICAL EFFICACY SURVIVAL STUDIES IN MALE AND FEMALE MINIPIGS WITH
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $13.0M |
| Current contract value | $13.0M |
| Potential contract value / ceiling | $94.8M |
| Start date | Jul 1, 2019 |
| Current end date | Feb 15, 2023 |
| Potential end date | Nov 10, 2023 |
| Latest award activity | Jul 25, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 25, 2025 | P00014 | $-11.9M | DE-OBLIGATE REMAINING FUNDS AND CLOSEOUT THE CONTRACT IN ITS ENTIRETY. |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.